The Full ASGCT 27th Annual Meeting Abstracts Collection is NOW LIVE! Click here to read the full collection.
Learn about new approvals and the state of the field for each quarter of 2022.
In Q4, gene therapies Hemgenix and Adstiladrin were approved in the U.S. for hemophilia B and bladder cancer, respectively.
In Q3, there were two new gene therapy approvals and three new RNA vaccine approvals, increases in dealmaking and fundraising, and development on anticancer indications within non-genetically modified cell therapy.
This quarter, a gene therapy for epidermolysis bullosa awaits approval in the U.S. and a CAR T-cell therapy for multiple myeloma awaits approval in China.
Highlights include approval of a CAR T-cell therapy for multiple myeloma in the U.S., filing for approval of an AAV5 gene therapy for hemophilia B in the EU and the UK, and more.
May 7-11, 2024 | Baltimore, MD
© 2000-2024 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico